+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetic Retinopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 286 Pages
  • October 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5699611
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Drugs In Development, 2022, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 5, 18, 14, 2, 83, 24 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively.

Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Report Coverage
  • Diabetic Retinopathy - Overview
  • Diabetic Retinopathy - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Diabetic Retinopathy - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Diabetic Retinopathy - Companies Involved in Therapeutics Development
  • Diabetic Retinopathy - Drug Profiles
  • A-717 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • A-91 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • aflibercept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • AIC-104 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • AMD/DR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • AMTX-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • APTA-1004 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • APX-3330 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • AR-13503 SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ARVN-006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • AST-202 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • AT-003 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • AVD-302 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • AVMX-116 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • axitinib SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • BAT-5906 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • bevacizumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • BI-764524 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • BI-765128 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Bi-specific Monoclonal Antibodies for Diabetic Retinopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Biologic for Diabetic Retinopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Biologics to Antagonize Semaphorin 3A for Diabetic Retinopathy and Retinopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile
  • Product Description
  • Mechanism Of Action
  • BNC-1601 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • BNN-27 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • bosentan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • brolucizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • BT-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • CCT-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • CD-52 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Cell Therapy For Diabetic Retinopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • cibinetide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • CLT-020 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • CRB-217 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • deulinoleate ethyl - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Diabetic Retinopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Drug for Diabetic Retinopathy and Retinopathy of Prematurity - Drug Profile
  • Product Description
  • Mechanism Of Action
  • EB-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • EB-105 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • EG-401 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • EG-Mirotin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ELB-00824 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • emixustat hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ENN-0403 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ENN-106 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • faricimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • FB-216A12 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • fenofibrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • finerenone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • FNP-120 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • FP-008 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Fusion Protein to Activate Caspases for Age Related Macular Degeneration, Diabetic Retinopathy and Solid Tumors - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Gene Therapy for Diabetes Induced Eye Complications - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Gene Therapy for Diabetic Retinopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Gene Therapy for Diabetic Retinopathy, Neurodegenerative Diseases and Wet Macular Degeneration - Drug Profile
  • Product Description
  • Mechanism Of Action
  • GLY-230 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • GYT-088 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • HL-190 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • HP-TAT - Drug Profile
  • Product Description
  • Mechanism Of Action
  • IM-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • imatinib mesylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • IVMED-60 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • JP-153 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • KIO-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • KNP-301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • KSI-501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • KTH-223 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • LKA-651 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • MDH-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • MDH-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • metformin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Monoclonal Antibodies for Age Related Macular Degeneration and Diabetic Retinopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Monoclonal Antibodies for Diabetic Retinopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Monoclonal Antibodies to Inhibit SCG3 for Oncology, Ophthalmology and Diabetic Complications - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Monoclonal Antibody for Diabetic Retinopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Monoclonal Antibody to Agonize Frizzled receptor 4 and LRP5 for Diabetic Retinopathy and Retinopathy of Prematurity - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • MR-MC-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • MS-553 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • NAV-2729 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • NB-2222 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • New Chemical Entities - Drug Profile
  • Product Description
  • Mechanism Of Action
  • NG-004 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • NM-108 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • NN-2101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • NS-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • NTX-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • OCU-200 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • OCX-063 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • OPL-0401 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • OTT-166 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • P-016 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Peptagon - Drug Profile
  • Product Description
  • Mechanism Of Action
  • PF-07 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • PL-8177 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • PL-8331 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • PL-9643 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • PL-9654 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • PMC-401 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • PMC-403 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Protein for Metabolic Disorders, Oncology and Ophthalmology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • PT-698 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • PTG-6 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ranibizumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ranibizumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ranibizumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ranibizumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ranibizumab SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • RBM-008 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • RC-28 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • REG-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Resolvine ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Retinopathies - Drug Profile
  • Product Description
  • Mechanism Of Action
  • RG-7774 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • RGX-314 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • RO-5461111 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • RPEC-1009a - Drug Profile
  • Product Description
  • Mechanism Of Action
  • RT-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • runcaciguat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SB-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SBT-200 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SER-130 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecule for Chronic Kidney Disease and Diabetic Retinopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecule to Block Cav1.3 and Free Radicals for Central Nervous System, Metabolic Disorders and Cardiovascular Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecule to Inhibit TRAP1 for Diabetic Retinopathy and Wet Age Related Macular Degeneration - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules to Agonize Sigma-1 Receptor for Metabolic and Central Nervous System Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules to Antagonize Renin-Prorenin Receptor for End-Organ Damage - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules to Inhibit ARF6 for Macular Degeneration and Diabetic Retinopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules to Inhibit PDGFR and VEGFR for Diabetic Retinopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules to Inhibit VAP-1 for Ophthalmology and Acute Respiratory Distress Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • sorafenib tosylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Spx-815 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ST-266 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Stem Cell Therapy for Diabetic Retinopathy, Peripheral Arterial Disease and Unspecified Cardiovascular Disorders, and Unspecified Indication - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Stem Cell Therapy for Ophthalmology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SYL-136001v10 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SYL-1801 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Synthetic Peptide for Age-Related Macular Degeneration and Diabetic Retinopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SZN-413 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • tarcocimab tedromer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • TATX-21 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • TGT-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • THR-687 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Tie2/VEGF bi-specific - Drug Profile
  • Product Description
  • Mechanism Of Action
  • TMi-018 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • tonabersat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • TOPV-122 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • TRV-32R - Drug Profile
  • Product Description
  • Mechanism Of Action
  • UBX-1325 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • UBX-1967 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • UBX-2050 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • VLTR-557 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • vorolanib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • VT-1001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Wnt-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • XW-006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • YDB-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ziv-aflibercept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Diabetic Retinopathy - Dormant Projects
  • Diabetic Retinopathy - Discontinued Products
  • Diabetic Retinopathy - Product Development Milestones
  • Featured News & Press Releases
  • Oct 19, 2022: OcuTerra reports publication of OTT166 safety and biological activity data from phase 1b study in diabetic eye disease
  • Oct 14, 2022: Ocuphire Pharma hosting Key Opinion Leader event on oral APX3330 for diabetic eye disease
  • Sep 29, 2022: EyePoint Pharmaceuticals announces first patient dosed in phase 2 PAVIA clinical trial of EYP-1901 for the treatment of non-proliferative diabetic retinopathy
  • Sep 26, 2022: Surrozen publishes study in Translational Vision Science and Technology demonstrating the promise of SZN-413 in preclinical models of diabetic retinopathy
  • Sep 19, 2022: Coherus to launch CIMERLI (ranibizumab-eqrn) in the United States on October 3, 2022
  • Sep 08, 2022: Ocuphire Pharma announces last patient completes final visit in ZETA-1 phase 2b 24-week trial of oral APX3330 in diabetic retinopathy
  • Aug 18, 2022: Valo Health announces first patient dosed in the OPL-0401 phase 2 study of an oral ROCK1/2 inhibitor for the treatment of non-proliferative diabetic retinopathy
  • Aug 05, 2022: Kodiak Sciences completes enrollment in GLOW phase 3 clinical trial of Tarcocimab Tedromer (KSI-301) in patients with non-proliferative diabetic retinopathy
  • Aug 02, 2022: FDA approves Coherus' CIMERLI (ranibizumab-eqrn) as the first and only interchangeable biosimilar to Lucentis for all five indications, with 12 months of interchangeability exclusivity
  • Aug 02, 2022: OcuTerra Therapeutics announces first patient dosed in OTT166 phase 2 DR:EAM clinical trial for diabetic retinopathy
  • Jun 29, 2022: Ocuphire granted new U.S. patent for late-stage oral drug candidate APX3330 for use in diabetics and announces new peer-reviewed APX3330 publication
  • Jun 29, 2022: EYLEA (aflibercept) injection sBLA for Every 16-week dosing regimen in patients with diabetic retinopathy accepted for FDA review
  • Jun 11, 2022: Ocuphire to present new interim masked safety data for oral APX3330 in Diabetics at Annual Macula Society Meeting
  • May 11, 2022: Ocuphire Pharma announces upcoming presentations at the Retina World Congress, clinical trials at the Summit, and the H.C. Wainwright Global Investment Conference
  • May 02, 2022: Palatin to present on PL-9654 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development for Diabetic Retinopathy, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Diabetic Retinopathy - Dormant Projects, 2022
  • Diabetic Retinopathy - Discontinued Products, 2022
List of Figures
  • Number of Products under Development for Diabetic Retinopathy, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Top 10 Routes of Administration, 2022
  • Number of Products by Stage and Top 10 Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • A6 Pharmaceuticals LLC
  • AbbVie Inc
  • Aerie Pharmaceuticals Inc
  • Ailon Co Ltd
  • Amytrx Therapeutics Inc
  • Angios GmbH
  • AntlerA Therapeutics Inc
  • Apexian Pharmaceuticals Inc
  • Applied Therapeutics Inc
  • AptaBio Therapeutics Inc
  • Aptamer Sciences Inc
  • Araim Pharmaceuticals Inc
  • Arctic Vision Shanghai Biotechnology Co Ltd
  • Ascentage Pharma Group International
  • Athenex Inc
  • Aviceda Therapeutics Inc
  • Avirmax Inc
  • Bayer AG
  • BetaStem Therapeutics Inc
  • Bio-Thera Solutions Ltd
  • Boehringer Ingelheim International GmbH
  • Bonac Corp
  • Caregen Co Ltd
  • CCRP Therapeutics GmbH
  • Cell Care Therapeutics Inc
  • Celros Biotech Co Ltd
  • Charlesson LLC
  • Clayton Biotechnologies Inc
  • Coherus BioSciences Inc
  • Connexin Therapeutics Inc
  • Curative Biotechnology Inc
  • Eluminex Biosciences Ltd
  • Ennovabio
  • Epigen Biosciences Inc
  • Everglades Biopharma LLC
  • Excitant Therapeutics LLC
  • EyeGene Inc
  • EyePoint Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Foresee Pharmaceuticals Co Ltd
  • Frontbio Co Ltd
  • Generium
  • Glycadia Inc
  • Grupo Ferrer Internacional SA
  • Guangzhou Magpie Pharmaceutical Co Ltd
  • HanAll Biopharma Co Ltd
  • ImmunAbs Inc
  • Inflammx Therapeutics Inc
  • iRegene Therapeutics Co Ltd
  • iVeena Delivery Systems Inc
  • jCyte Inc
  • Kalos Therapeutics Inc
  • Kanaph Therapeutics Inc
  • Kato Pharmaceuticals Inc
  • Kiora Pharmaceuticals Inc
  • Kodiak Sciences Inc
  • Kubota Vision Inc
  • Luye Pharma Group Ltd
  • Mabion SA
  • MD Healthcare Inc
  • MingSight Pharmaceuticals Inc
  • Mirae Cell Bio Co Ltd
  • NanoPharmaceuticals LLC
  • NB Health Laboratory Co Ltd
  • NeuMedics Inc
  • Neurodegeneration Therapeutics Inc
  • NGM Biopharmaceuticals Inc
  • Novago Therapeutics AG
  • Novartis AG
  • Novelty Nobility Inc
  • Noveome Biotherapeutics Inc
  • OccuRx Pty Ltd
  • Ocugen Inc
  • Ocular Therapeutix Inc
  • OcuNexus Therapeutics Inc
  • OcuTerra Therapeutics Inc
  • OliPass Corporation
  • OM Pharma Ltd
  • Opera Therapeutics
  • Oxurion NV
  • Palatin Technologies Inc
  • Phanes Therapeutics Inc
  • PharmAbcine Inc
  • Pinotbio Inc
  • Praetego Inc
  • Profarma
  • Ranger Biotechnologies AS
  • Regenerate Therapeutics Inc
  • Regeneron Pharmaceuticals Inc
  • RemeGen Co Ltd
  • Retinset SL
  • Retrotope Inc
  • Reven Holdings Inc
  • Ribomic Inc
  • Sciwind Biosciences Co Ltd
  • Serodus ASA
  • Shanghai Henlius Biotech Inc
  • Shenzhen Evergreen Therapeutics Co Ltd
  • Shilpa Medicare Ltd
  • SIFI SpA
  • Singh Biotechnology LLC
  • SiNOPSEE Therapeutics Pte Ltd
  • Skye Bioscience Inc
  • Skyran Biologics Inc
  • SmartinBio
  • SunBio Inc
  • Sylentis SAU
  • Talem Therapeutics Inc
  • Teraclon IDF SL
  • ToolGen Inc
  • Topadur Pharma AG
  • Translatum Medicus Inc
  • Unity Biotechnology Inc
  • USA Elixiria Biotech Inc
  • Valitor Inc
  • Valo Health LLC
  • Vascugen Inc
  • VESSL Therapeutics Ltd
  • Vitreo Pharma Inc
  • Wntgen LLC
  • Xbrane Biopharma AB
  • Xequel Bio Inc
  • YD Life Science Co
  • Zih Yuan Tang Biotechnology Co Ltd

Related Topics

Related Reports

Diabetic Retinopathy - Pipeline Insight, 2024 - Product Image

Diabetic Retinopathy - Pipeline Insight, 2024

  • Clinical Trials
  • 210 Pages
  • Global
From
Macular Edema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Macular Edema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 132 Pages
  • Global
From
Proliferative Diabetic Retinopathy - Pipeline Insight, 2024 - Product Image

Proliferative Diabetic Retinopathy - Pipeline Insight, 2024

  • Drug Pipelines
  • 40 Pages
  • Global
From
Retinal Edema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Retinal Edema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 135 Pages
  • Global
From
Diabetic Retinopathy - Global Clinical Trials Review, 2024 - Product Image

Diabetic Retinopathy - Global Clinical Trials Review, 2024

  • Clinical Trials
  • 464 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.